Literature DB >> 20031679

Poor 1-year outcomes after percutaneous coronary interventions in systemic lupus erythematosus: report from the National Heart, Lung, and Blood Institute Dynamic Registry.

Kathleen Maksimowicz-McKinnon1, Faith Selzer, Susan Manzi, Kevin E Kip, Suresh R Mulukutla, Oscar C Marroquin, Thomas C Smitherman, Lewis H Kuller, David O Williams, Mary Chester M Wasko.   

Abstract

BACKGROUND: Women with systemic lupus erythematosus (SLE) have premature and accelerated atherosclerosis. Although percutaneous coronary intervention (PCI) is used frequently to treat coronary artery disease in SLE, little is known regarding PCI outcomes immediately after PCI and after discharge. METHODS AND
RESULTS: Baseline demographic, procedure-related, and adverse outcome data on consecutive patients undergoing PCI during 5 recruitment "waves" of the National Heart, Lung, and Blood Institute Dynamic Registry across 23 clinical centers were collected. SLE patients (n=28) were compared with non-SLE patients (n=3385). SLE patients were younger and more often female in comparison with non-SLE patients undergoing PCI. SLE patients were less likely than non-SLE patients to have hyperlipidemia but had a similar prevalence of hypertension, diabetes mellitus, and tobacco use. The prevalence of multivessel disease was similar between groups. Initial intervention success (by angiographic definition) was not significantly different between groups. At 1 year, SLE patients were more likely to experience a myocardial infarction (15.6% versus 4.8%, P=0.01) and more often required repeat PCI (31.3% versus 11.8%, P=0.009) than non-SLE patients, even after adjustment for important covariates.
CONCLUSIONS: SLE patients had significantly worse cardiovascular outcomes at 1 year than non-SLE patients. Even considering the small number of SLE patients, these differences were striking. Further study is warranted to explore other factors potentially accounting for this disparity, including SLE disease activity and duration, presence of hypercoagulable state, and immunosuppressive therapy.

Entities:  

Mesh:

Year:  2008        PMID: 20031679      PMCID: PMC2945900          DOI: 10.1161/CIRCINTERVENTIONS.108.788745

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  33 in total

1.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

2.  Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.

Authors:  Mehdi H Shishehbor; Ronnier J Aviles; Marie-Luise Brennan; Xiaoming Fu; Marlene Goormastic; Gregory L Pearce; Noyan Gokce; John F Keaney; Marc S Penn; Dennis L Sprecher; Joseph A Vita; Stanley L Hazen
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

3.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

4.  The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients.

Authors:  B H Bulkley; W C Roberts
Journal:  Am J Med       Date:  1975-02       Impact factor: 4.965

5.  C5b-9 terminal complement complex assembly on apoptotic cells in human arterial wall with atherosclerosis.

Authors:  Florin Niculescu; Teodora Niculescu; Horea Rus
Journal:  Exp Mol Pathol       Date:  2004-02       Impact factor: 3.362

6.  Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus.

Authors:  Michael M Ward
Journal:  Arthritis Rheum       Date:  2004-10

7.  Acquired activated protein C resistance, high tissue factor expression, and hyper-homocysteinemia in systemic lupus erythematosus.

Authors:  D Oh; S H Kim; M S Kang; N K Kim; N S Chang; B W Na; S Y Chung; S Park; C S Cho
Journal:  Am J Hematol       Date:  2003-02       Impact factor: 10.047

8.  Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.

Authors:  James L Orford; Panayotis Fasseas; Steven Melby; Kelli Burger; Steven R Steinhubl; David R Holmes; Peter B Berger
Journal:  Am Heart J       Date:  2004-03       Impact factor: 4.749

9.  Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study.

Authors:  Ian N Bruce; Murray B Urowitz; Dafna D Gladman; Dominique Ibañez; George Steiner
Journal:  Arthritis Rheum       Date:  2003-11

10.  Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein.

Authors:  Seiichi Kobayashi; Nobutaka Inoue; Yoshitaka Ohashi; Mitsuyoshi Terashima; Kiyoko Matsui; Takao Mori; Hideki Fujita; Kojiro Awano; Katsuya Kobayashi; Hiroshi Azumi; Junya Ejiri; Ken-ichi Hirata; Seinosuke Kawashima; Yoshitake Hayashi; Hiroshi Yokozaki; Hiroshi Itoh; Mitsuhiro Yokoyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-12       Impact factor: 8.311

View more
  8 in total

Review 1.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 2.  Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.

Authors:  Justin C Mason; Peter Libby
Journal:  Eur Heart J       Date:  2014-11-27       Impact factor: 29.983

Review 3.  Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

Authors:  Deborah P M Symmons; Sherine E Gabriel
Journal:  Nat Rev Rheumatol       Date:  2011-05-31       Impact factor: 20.543

4.  Opposing effects of monomeric and pentameric C-reactive protein on endothelial progenitor cells.

Authors:  I Ahrens; H Domeij; S U Eisenhardt; D Topcic; M Albrecht; E Leitner; K Viitaniemi; J B Jowett; M Lappas; C Bode; I Haviv; K Peter
Journal:  Basic Res Cardiol       Date:  2011-05-12       Impact factor: 17.165

Review 5.  The increased cardiovascular risk in patients affected by autoimmune diseases: review of the various manifestations.

Authors:  Alessandro Durante; Sofia Bronzato
Journal:  J Clin Med Res       Date:  2015-04-08

Review 6.  Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.

Authors:  Pravesh Kumar Bundhun; Kamini Devi Boodhoo; Man-Yun Long; Meng-Hua Chen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 7.  Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.

Authors:  Vítor Teixeira; Lai-Shan Tam
Journal:  Front Med (Lausanne)       Date:  2018-01-29

8.  Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries.

Authors:  Ole Ahlehoff; Jesper Lindhardsen; Gunnar H Gislason; Jonas B Olesen; Mette Charlot; Lone Skov; Christian Torp-Pedersen; Peter R Hansen
Journal:  BMC Cardiovasc Disord       Date:  2012-09-24       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.